Eduardo Seclén, Ph.D. is Director of Gene Editing at NV Therapeutics in Berkeley, California.

Edu has over 17 years of experience in cell and gene therapy development, with a focus on hematopoietic stem cells and T cells. During his time at Universidad Complutense de Madrid and University of Southern California, he focused on foundational HIV research and gene editing strategies for HIV cures. At Cellectis, he led programs advancing gene therapies for sickle cell disease and lysosomal storage disorders.